113 related articles for article (PubMed ID: 38767352)
1. An mRNA-LNP-based Lassa virus vaccine induces protective immunity in mice.
Hashizume M; Takashima A; Iwasaki M
J Virol; 2024 Jun; 98(6):e0057824. PubMed ID: 38767352
[TBL] [Abstract][Full Text] [Related]
2. A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene.
Cai Y; Ye C; Cheng B; Nogales A; Iwasaki M; Yu S; Cooper K; Liu DX; Hart R; Adams R; Brady T; Postnikova EN; Kurtz J; St Claire M; Kuhn JH; de la Torre JC; Martínez-Sobrido L
mBio; 2020 Feb; 11(1):. PubMed ID: 32098811
[TBL] [Abstract][Full Text] [Related]
3. A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic Region.
Cai Y; Iwasaki M; Motooka D; Liu DX; Yu S; Cooper K; Hart R; Adams R; Burdette T; Postnikova EN; Kurtz J; St Claire M; Ye C; Kuhn JH; Martínez-Sobrido L; de la Torre JC
mBio; 2020 Mar; 11(2):. PubMed ID: 32209677
[TBL] [Abstract][Full Text] [Related]
4. Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever.
Branco LM; Grove JN; Geske FJ; Boisen ML; Muncy IJ; Magliato SA; Henderson LA; Schoepp RJ; Cashman KA; Hensley LE; Garry RF
Virol J; 2010 Oct; 7():279. PubMed ID: 20961433
[TBL] [Abstract][Full Text] [Related]
5. Molecular Engineering of a Mammarenavirus with Unbreachable Attenuation.
Sakabe S; Cubitt B; Martinez-Sobrido L; de la Torre JC
J Virol; 2023 Jan; 97(1):e0138522. PubMed ID: 36533953
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis of Lassa fever virus infection: I. Susceptibility of mice to recombinant Lassa Gp/LCMV chimeric virus.
Lee AM; Cruite J; Welch MJ; Sullivan B; Oldstone MB
Virology; 2013 Aug; 442(2):114-21. PubMed ID: 23684417
[TBL] [Abstract][Full Text] [Related]
7. Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins.
Wang M; Jokinen J; Tretyakova I; Pushko P; Lukashevich IS
Vaccine; 2018 Jan; 36(5):683-690. PubMed ID: 29287681
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein.
Rodriguez-Carreno MP; Nelson MS; Botten J; Smith-Nixon K; Buchmeier MJ; Whitton JL
Virology; 2005 Apr; 335(1):87-98. PubMed ID: 15823608
[TBL] [Abstract][Full Text] [Related]
9. Evolution of recombinant lymphocytic choriomeningitis virus/Lassa virus in vivo highlights the importance of the GPC cytosolic tail in viral fitness.
Sommerstein R; Ramos da Palma J; Olschläger S; Bergthaler A; Barba L; Lee BP; Pasquato A; Flatz L
J Virol; 2014 Aug; 88(15):8340-8. PubMed ID: 24829355
[TBL] [Abstract][Full Text] [Related]
10. Innate and adaptive immune control of genetically engineered live-attenuated arenavirus vaccine prototypes.
Pinschewer DD; Flatz L; Steinborn R; Horvath E; Fernandez M; Lutz H; Suter M; Bergthaler A
Int Immunol; 2010 Sep; 22(9):749-56. PubMed ID: 20584765
[TBL] [Abstract][Full Text] [Related]
11. Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever.
Abreu-Mota T; Hagen KR; Cooper K; Jahrling PB; Tan G; Wirblich C; Johnson RF; Schnell MJ
Nat Commun; 2018 Oct; 9(1):4223. PubMed ID: 30310067
[TBL] [Abstract][Full Text] [Related]
12. Arenavirus Genome Rearrangement for the Development of Live Attenuated Vaccines.
Cheng BY; Ortiz-Riaño E; de la Torre JC; Martínez-Sobrido L
J Virol; 2015 Jul; 89(14):7373-84. PubMed ID: 25972555
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of a protective intradermal DNA vaccine against lassa virus in cynomolgus macaques.
Jiang J; Banglore P; Cashman KA; Schmaljohn CS; Schultheis K; Pugh H; Nguyen J; Humeau LM; Broderick KE; Ramos SJ
Hum Vaccin Immunother; 2019; 15(9):2066-2074. PubMed ID: 31071008
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Lassa virus vaccine immunogenicity in a CBA/J-ML29 mouse model.
Goicochea MA; Zapata JC; Bryant J; Davis H; Salvato MS; Lukashevich IS
Vaccine; 2012 Feb; 30(8):1445-52. PubMed ID: 22234266
[TBL] [Abstract][Full Text] [Related]
15. Development of live-attenuated arenavirus vaccines based on codon deoptimization.
Cheng BY; Ortiz-Riaño E; Nogales A; de la Torre JC; Martínez-Sobrido L
J Virol; 2015 Apr; 89(7):3523-33. PubMed ID: 25589652
[TBL] [Abstract][Full Text] [Related]
16. Lassa Virus Vaccine Candidate ML29 Generates Truncated Viral RNAs Which Contribute to Interfering Activity and Attenuation.
Johnson DM; Cubitt B; Pfeffer TL; de la Torre JC; Lukashevich IS
Viruses; 2021 Jan; 13(2):. PubMed ID: 33573250
[TBL] [Abstract][Full Text] [Related]
17. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.
Safronetz D; Mire C; Rosenke K; Feldmann F; Haddock E; Geisbert T; Feldmann H
PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003736. PubMed ID: 25884628
[TBL] [Abstract][Full Text] [Related]
18. The Pan-ErbB tyrosine kinase inhibitor afatinib inhibits multiple steps of the mammarenavirus life cycle.
Mizuma K; Takashima A; Cubitt B; de la Torre JC; Iwasaki M
Virology; 2022 Nov; 576():83-95. PubMed ID: 36183499
[TBL] [Abstract][Full Text] [Related]
19. A multivalent vaccination strategy for the prevention of Old World arenavirus infection in humans.
Botten J; Whitton JL; Barrowman P; Sidney J; Whitmire JK; Alexander J; Kotturi MF; Sette A; Buchmeier MJ
J Virol; 2010 Oct; 84(19):9947-56. PubMed ID: 20668086
[TBL] [Abstract][Full Text] [Related]
20. Identification of Common CD8
Sakabe S; Hartnett JN; Ngo N; Goba A; Momoh M; Sandi JD; Kanneh L; Cubitt B; Garcia SD; Ware BC; Kotliar D; Robles-Sikisaka R; Gangavarapu K; Branco LM; Eromon P; Odia I; Ogbaini-Emovon E; Folarin O; Okogbenin S; Okokhere PO; Happi C; Sabeti PC; Andersen KG; Garry RF; de la Torre JC; Grant DS; Schieffelin JS; Oldstone MBA; Sullivan BM
J Virol; 2020 Jun; 94(12):. PubMed ID: 32269122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
